Services
Upon reaching the design capacity in 2025, the following production volumes are planned: live vaccines (against Gumboro, Marek, Newcastle, ITL, infectious bronchitis, etc.) - more than 2 billion doses per year, inactivated vaccines (against Gumboro, Marek, Newcastle, ITL, infectious bronchitis, etc.) - more than 1 billion doses per year.
Project
This investment project (the “Project”) plans to build a plant for the production of immunobiological preparations (vaccines), immunomodulators and diagnostic tests that comply with the standards and requirements of Good Manufacturing Practice (GMP), ISO/IEC 17025, ISO 9001:2008 and ICH Q10. The planned production capacity will be more than 3 billion doses of vaccines per year. For the construction of the plant, a land plot of 1.35 hectares was allocated, which is at the disposal of the Company.
The implementation of the Project will allow to carry out the following tasks:
- creation of a full cycle of production of vaccines for industrial poultry farming with a division for SPF embryos;
- development of patent-protected anti-infective drugs and veterinary drugs.
NPP Antigen LLP is a manufacturer of biological and medicinal preparations. The company produces veterinary drugs annually in the amount of 50-70 million doses of preventive drugs and 60-70 million diagnostic tests. To implement the Project, together with potential investors, AntigenBioPharm Research and Production Center LLP will be established.
Market
- The market for animal vaccines is growing annually both domestically and internationally. According to Market Research Future, the global animal vaccine market will reach $13 billion by 2027, at a CAGR of 7% over the period 2021-2027. The highest growth rate is projected in the poultry vaccine segment, with a CAGR of 2021-2027. will reach 8.94%.
- The production of sera and vaccines used in veterinary medicine in the Republic of Kazakhstan in 2021 amounted to 188 tons, which is 82% less than in 2020. The compound average annual growth rate of production volumes for the period 2017-2021. reached 41%.
- Compliance with world standards. The Company's products will comply with global GMP, ISO/IEC 17025, ISO 9001:2008 and ICH Q10 standards. Within the framework of the Project, it is planned to introduce modern methods of control using reference strains of the World Health Organization (WHO).
- Company experience. The initiator has an extensive intellectual and material base, has a staff of highly qualified specialists. At the moment, the Initiator is already selling part of its products for export to the countries of Central Asia, Azerbaijan, Armenia and Georgia.
- Absence of competitors. The company will be the only manufacturer of immunobiological products for the industrial poultry industry that has its own division for SPF embryos.
To implement the Project, funding in the amount of USD 15,819 thousand is required, including:
- 70% (USD 11,073 thousand) - investor participation;
- 30% (USD 4,746 thousand) - own funds of NPP Antigen LLP.
The proposed financing structure and state support measures are indicative, the final financing structure and the stake in the Project will be determined based on the results of joint negotiations with the investor.
